Getting finasteride in the UK: the routes, and what changed

Prescription only, and the licence says so

Finasteride 1 mg film-coated tablets hold a UK marketing authorisation — the one read for this page is PL 49445/0009, held by Amarox Limited — indicated for "the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss". Its legal category is Prescription only medicine. That was read from the Summary of Product Characteristics on the electronic medicines compendium on 24 September 2026.

Prescription-only status is not a formality standing between a reader and a product. It is where a specific set of warnings is supposed to be discussed, and those warnings have been strengthened twice in three years.

What the pack now contains that it did not

The UK Summary of Product Characteristics records that mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with finasteride 1 mg, and that sexual dysfunction that may contribute to mood alterations, including suicidal ideation, has been reported in some patients. Patients are to be counselled to report such symptoms, and a patient reminder card about them is included in every pack.

The card is there because of a regulatory decision with a date. The MHRA's Drug Safety Update of 29 April 2024 introduced it, following a safety review that also recorded reports of sexual dysfunction and psychiatric reactions.

What changed on 11 May 2026

The MHRA published a further Drug Safety Update — volume 19, issue 10 — after considering a European regulatory review and expert advice from the Commission on Human Medicines. Three things came out of it.

The product information for finasteride 1 mg was changed to say that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported without mood alterations. That second clause is the substantive change: the earlier framing ran the two together, and the new wording allows that one has been reported without the other.

A precautionary note was added to dutasteride, recording that "depressed mood, depression or suicidal ideation has been reported in patients receiving another medicine from the same class".

And the update published the Yellow Card counts to 31 May 2025: 170 reports of suicidal ideation for finasteride, including 19 fatal reports of suicide, and 5 reports for dutasteride, none fatal. Its own characterisation of the wider evidence is the sentence to hold onto: "the literature data showed mixed outcomes."

Two cautions about those counts, because they are routinely misused. Yellow Card reports are spontaneous reports of a suspicion, not confirmed cases, and there is no denominator published beside them — dividing them by any estimate of how many people have taken the drug produces a number that looks like an incidence and is not one. This page does not perform that division and you should be wary of any page that does.

The three routes to a prescription

They differ in who examines you, not in what the molecule is.

A GP. Free to see; the prescription generally is not, because pattern hair loss is not an NHS-funded indication. Expect a private prescription that you take to a pharmacy. A GP is also the right route if anything about the pattern is unusual, because the first question is whether this is pattern hair loss at all.

A dermatologist. The route when the diagnosis is the open question rather than the treatment — patchy loss, scarring, sudden shedding, anything with a scalp change alongside it. Private dermatology costs more than a GP appointment and buys a different kind of assessment.

A UK-regulated online prescriber. Convenient, and the thing to interrogate is the service rather than the drug. Who is the prescriber and where are they registered; what does the questionnaire actually ask and what would cause it to refuse; which pharmacy dispenses; what the subscription costs at renewal rather than at signup; and how cancellation works. A service that makes the medicine easy to obtain and the prescriber hard to identify has told you which of the two it is selling.

Why you never see it advertised here

Because that is prohibited. The Advertising Standards Authority's advice on hair-loss advertising is that prescription-only medicines must not be advertised to the public, under CAP Code rule 12.12, and it names prescription-strength finasteride and minoxidil as falling inside that. A clinic may advertise a consultation; it may not advertise the treatment.

This is why UK marketing for hair loss talks about "consultations", "treatment plans" and "clinically-backed options" rather than naming a drug. It is not coyness. It is the rule. Learning to read around it is a genuinely useful skill, and it is set out in reading a UK hair clinic advert.

What this page will not tell you

No dose, no frequency, no "how to take it", no comparison of one strength against another, and no view on whether you should. That is not squeamishness; it is the division of labour the prescription system exists to create. The label in the box and the prescriber who wrote it are the two sources that know your history, and neither of them is a website.

Nor will you find an opinion here on post-finasteride syndrome. What can be said from UK documents is what the MHRA published and how it characterised the literature, which is above. Anything beyond that would be this site adding confidence that its sources do not contain.

The cheap, unglamorous version

If a prescriber agrees a medicine is reasonable, a private prescription filled at an ordinary pharmacy is usually the least expensive way to hold it, and nobody pays this site anything when you do that. Generic finasteride 1 mg carries its own marketing authorisation, as the one quoted at the top of this page shows, and a licensed generic is a licensed medicine rather than a lesser version of one.

What is licensed in this country, at what legal distance from a shop shelf, is laid out in hair loss treatment in the UK. The tablet that is prescription only for a completely different illness is in oral minoxidil in the UK. And if surgery is the other half of the question you are weighing, the registers and the recourse routes are on hair transplants in the UK.